Study Design and Baseline Characteristics of the Finerenone Trial in Slowing Kidney Disease Progression in Diabetic Patients

Atmach Dovach; Kashtany Al Saad; Lipsk Haliem

doi:10.69725/imchp.v1i2.212

Authors

Atmach Dovach a. Department of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom Saudi of Arabia
Kashtany Al Saad b. Department of Nephrology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Lipsk Haliem c. Centre for Public Health, School of Medicine, Dentistry, and Biomedical Sciences, Queen’s University Belfast, Belfast, Northern Ireland, UK

DOI:

https://doi.org/10.69725/imchp.v1i2.212

Keywords:

Finerenone, Chronic Kidney Disease, Type 2 Diabetes, Cardiovascular Risk, Renoprotection

Abstract

Objectives - We investigate the safety and efficacy of finerenone in delaying CKD progression in patients with T2D.
Methods - A multicenter, randomized, double-blind, placebo-controlled trial was conducted in participants with T2D and CKD who were on standard therapy. Participants were randomized to finerenone or placebo. The main endpoint was a composite of decline in kidney function, progression to end-stage kidney disease (ESKD), and cardiovascular death. Statistical analysis included Cox proportional hazard models and subgroup assessments to evaluate treatment consistency.
Results - Finerenone showed a significant protective effect on kidney function and decreased the risk of cardiovascular events. Amongst participants, treatment was associated with improvements in albuminuria and had a consistent safety profile. The efficacy was also confirmed across all patient demographics in subgroup analyses. The most notable adverse event was hyperkalemia, but this was usually manageable in line with standard clinical care.
Novelty - This study presents strong evidence for the use of finerenone as a therapy for CKD in T2D, underscoring its renoprotective effects independent of standard care. This trial, unlike prior research concentrating on glucose or blood pressure control, emphasizes direct benefits on kidney health.
Research implications - Importantly, these data further support the use of early treatment with finerenone to reduce decline in kidney function and cardiovascular risk. Longer studies in wider populations are needed to evaluate long-term benefits.

Author Biographies

Atmach Dovach, a. Department of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom Saudi of Arabia

Dr Atmach Dovach
Department of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom Saudi of Arabia
Kashtany Al Saad, b. Department of Nephrology, Hacettepe University Faculty of Medicine, Ankara, Turkey

Department of Nephrology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Lipsk Haliem , c. Centre for Public Health, School of Medicine, Dentistry, and Biomedical Sciences, Queen’s University Belfast, Belfast, Northern Ireland, UK

Reserach
Centre for Public Health, School of Medicine, Dentistry, and Biomedical Sciences, Queen’s University Belfast, Belfast, Northern Ireland, UK

References

Bakris, George. 2024. “Mineralocorticoid Receptor Antagonists and Reno-Protection: What’s the Evidence & Where Do They Fit? A Guide for Non-Specialists.” Diabetes, Obesity and Metabolism 26(S6):33–42. doi: https://doi.org/10.1111/dom.15617.

Barrera-Chimal, Jonatan, Frédéric Jaisser, and Hans-Joachim Anders. 2022. “The Mineralocorticoid Receptor in Chronic Kidney Disease.” British Journal of Pharmacology 179(13):3152–64. doi: https://doi.org/10.1111/bph.15734.

Chen, Qi, Yingnan Liang, Jiaxin Yan, Yiran Du, Mengbi Li, Zhenjie Chen, and Jingwei Zhou. 2023. “Efficacy and Safety of Non-Steroidal Mineralocorticoid Receptor Antagonists for Renal Outcomes: A Systematic Review and Meta-Analysis.” Diabetes Research and Clinical Practice 195:110210. doi: https://doi.org/10.1016/j.diabres.2022.110210.

Davidson, Jaime A. 2019. “SGLT2 Inhibitors in Patients with Type 2 Diabetes and Renal Disease: Overview of Current Evidence.” Postgraduate Medicine 131(4):251–60. doi: 10.1080/00325481.2019.1601404.

Guedes, Murilo, and Roberto Pecoits-Filho. 2022. “Can We Cure Diabetic Kidney Disease? Present and Future Perspectives from a Nephrologist’s Point of View.” Journal of Internal Medicine 291(2):165–80. doi: https://doi.org/10.1111/joim.13424.

Ho, Peter T. C. 2022. “The Pharma/Biotech Model for Drug Development: Implications for Pediatric Cancer Therapeutics BT - Pediatric Cancer Therapeutics Development.” Pp. 89–107 in, edited by J. DiMartino, G. H. Reaman, and F. O. Smith. Cham: Springer International Publishing.

Khojasteh, S. Cyrus, Harvey Wong, Donglu Zhang, and Cornelis E. C. A. Hop. 2022. “DMPK Lead Optimization BT - Discovery DMPK Quick Guide: Guide to Data Interpretation and Integration.” Pp. 63–139 in, edited by S. C. Khojasteh, H. Wong, D. Zhang, and C. E. C. A. Hop. Cham: Springer International Publishing.

Kovesdy, Csaba P. 2022. “Epidemiology of Chronic Kidney Disease: An Update 2022.” Kidney International Supplements 12(1):7–11. doi: https://doi.org/10.1016/j.kisu.2021.11.003.

Lv, Ji-Cheng, and Lu-Xia Zhang. 2019. “Prevalence and Disease Burden of Chronic Kidney Disease BT - Renal Fibrosis: Mechanisms and Therapies.” Pp. 3–15 in, edited by B.-C. Liu, H.-Y. Lan, and L.-L. Lv. Singapore: Springer Singapore.

Malek, Vajir, Sachin V Suryavanshi, Nisha Sharma, Yogesh A. Kulkarni, Shrikant R. Mulay, and Anil Bhanudas Gaikwad. 2021. “Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope! BT - Reviews of Physiology, Biochemistry and Pharmacology.” Pp. 31–71 in, edited by S. H. F. Pedersen. Cham: Springer International Publishing.

Malík, Jan, Vilém Danzig, Vladimíra Bednářová, and Zdenka Hrušková. 2018. “Echocardiography in Patients with Chronic Kidney Diseases.” Cor et Vasa 60(3):e287–95. doi: https://doi.org/10.1016/j.crvasa.2017.07.008.

Mbanya, Jean Claude, Pablo Aschner, Juan J. Gagliardino, Hasan İlkova, Fernando Lavalle, Ambady Ramachandran, Jean-Marc Chantelot, and Juliana C. N. Chan. 2021. “Screening, Prevalence, Treatment and Control of Kidney Disease in Patients with Type 1 and Type 2 Diabetes in Low-to-Middle-Income Countries (2005–2017): The International Diabetes Management Practices Study (IDMPS).” Diabetologia 64(6):1246–55. doi: 10.1007/s00125-021-05406-6.

Mende, Christian W. 2022. “Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape.” Advances in Therapy 39(1):148–64. doi: 10.1007/s12325-021-01994-2.

Pecoits-Filho, Roberto, Beatriz Yanez Jimenez, Gloria E. Ashuntantang, Federica de Giorgi, Salvatore De Cosmo, Per-Henrik Groop, Adrien Liew, Anne Hradsky, Roberto Pontremoli, Laura Sola, and Antonio Ceriello. 2023. “Renewing the Fight: A Call to Action for Diabetes and Chronic Kidney Disease.” Diabetes Research and Clinical Practice 203:110902. doi: https://doi.org/10.1016/j.diabres.2023.110902.

Penno, Giuseppe, Anna Solini, Emanuela Orsi, Enzo Bonora, Cecilia Fondelli, Roberto Trevisan, Monica Vedovato, Franco Cavalot, Gianpaolo Zerbini, Olga Lamacchia, Antonio Nicolucci, Giuseppe Pugliese, Giuseppe Pugliese, Giuseppe Penno, Anna Solini, Enzo Bonora, Emanuela Orsi, Roberto Trevisan, Luigi Laviola, Antonio Nicolucci, and for the Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. 2021. “Insulin Resistance, Diabetic Kidney Disease, and All-Cause Mortality in Individuals with Type 2 Diabetes: A Prospective Cohort Study.” BMC Medicine 19(1):66. doi: 10.1186/s12916-021-01936-3.

Qin, Kaili, Jianbo Qing, Qian Wang, and Yafeng Li. 2024. “Epidemiological Shifts in Chronic Kidney Disease: A 30-Year Global and Regional Assessment.” BMC Public Health 24(1):3519. doi: 10.1186/s12889-024-21065-9.

Sebastian, Sneha Annie, Inderbir Padda, and Gurpreet Johal. 2024. “Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A State-of-the-Art Review.” Current Problems in Cardiology 49(2):102344. doi: https://doi.org/10.1016/j.cpcardiol.2023.102344.

Seidu, Samuel, Setor K. Kunutsor, Pinar Topsever, and Kamlesh Khunti. 2022. “Benefits and Harms of Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT2-I) and Renin–Angiotensin–Aldosterone System Inhibitors (RAAS-I) versus SGLT2-Is Alone in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Endocrinology, Diabetes & Metabolism 5(1):e00303. doi: https://doi.org/10.1002/edm2.303.

Shenoy, Srinivas Vinayak, Shankar Prasad Nagaraju, Mohan Varadanayakanahalli Bhojaraja, Ravindra Attur Prabhu, Dharshan Rangaswamy, and Indu Ramachandra Rao. 2021. “Sodium-Glucose Cotransporter-2 Inhibitors and Non-Steroidal Mineralocorticoid Receptor Antagonists: Ushering in a New Era of Nephroprotection beyond Renin-Angiotensin System Blockade.” Nephrology 26(11):858–71. doi: https://doi.org/10.1111/nep.13917.

Stepanova, Natalia. 2024. “SGLT2 Inhibitors in Peritoneal Dialysis: A Promising Frontier toward Improved Patient Outcomes.” Renal Replacement Therapy 10(1):5. doi: 10.1186/s41100-024-00523-5.

Yau, Kevin, Atit Dharia, Ibrahim Alrowiyti, and David Z. I. Cherney. 2022. “Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations.” Kidney International Reports 7(7):1463–76. doi: https://doi.org/10.1016/j.ekir.2022.04.094.